7.4.4.1. treatment-naïve patients clear-cell metastatic rcc. combination pembrolizumab plus axitinib well nivolumab plus cabozantinib lenvatinib plus pembrolizumab standard care imdc-risk patients ipilimumab plus nivolumab imdc intermediate- poor-risk patients (figure 7.1). therefore, role vegfr-tkis alone front-line mrcc superseded imdc intermidiate poor risk. imdc favorable group, absence os benefit options acceptable. sunitinib, pazopanib, cabozantinib (imdc intermediate- poor-risk disease), remain alternative treatment options patients cannot receive tolerate immune checkpoint inhibition setting (figure 7.1). 7.4.4.1.1. sequencing systemic therapy clear-cell metastatic rcc sequencing targeted therapies established mrcc maximises outcomes . pembrolizumab plus axitinib, nivolumab plus cabozantinib, lenvatinib plus pembrolizumab nivolumab plus ipilimumab new standard care front-line therapy imdc intermediate/poor. impact front-line immune checkpoint inhibition subsequent therapies unclear. randomised data patients disease refractory either nivolumab plus ipilimumab tki plus io first-line setting limited. sequencing immune checkpoint inhibition atezolizumab demonstrate orr, pfs , os benefit single agent tki contact 03 . prospective data cabozantinib, tivozanib, axitinib available patients progressing immunotherapy, studies focus solely front-line setting, involve subset analyses, small definitive conclusions . use mtor inhibitors considered vegf-targeted therapy refractory disease outperformed vegf-targeted therapies mrcc belzutifan . drug choice third-line setting, immune checkpoint inhibitor combinations subsequent vegf-targeted therapy, unknown. panel recommends subsequent agent approved vegf-refractory disease, exception re-challenge immune checkpoint blockade. cabozantinib agent vegf-refractory disease rct data showing survival advantage used preferentially . axitinib positive pfs data vegf- refractory disease. sorafenib everolimus outperformed agents vegf-refractory disease therefore less attractive . lenvatinib plus everolimus combination appears superior everolimus alone granted ema regulatory approval based randomised phase ii data. alternative despite availability phase ii data . shown study also included patients icis, tivozanib provides pfs superiority sorafenib vegf-refractory disease . 7.4.4.1.2. summary evidence recommendations immunotherapy cc-mrcc summary evidenceletreatment-naïve patientscurrently, pd-l1 expression used patient selection.2bthe combination nivolumab ipilimumab treatment-naïve patients cc-mrcc imdc intermediate- poor risk demonstrated os orr benefits compared sunitinib alone.1bthe combination pembrolizumab plus axitinib, lenvatinib plus pembrolizumab nivolumab plus cabozantinib treatment-naïve patients cc-mrcc demonstrated pfs, os orr benefits compared sunitinib itt population.1bthe combination pembrolizumab plus axitinib, lenvatinib plus pembrolizumab nivolumab plus cabozantinib treatment-naïve patients cc-mrcc imdc favorable subgroups demonstrated pfs orr benefits compared sunitinib, without os improvememt.2btriplet cabo-nivo-ipi demonsrated pfs benefit nivo-ipi.1bnivolumab plus ipilimumab, pembrolizumab plus axitinib, nivolumab plus cabozantinib lenvatinib plus pembrolizumab administered centres experience immune combination therapy appropriate supportive care within context multidisciplinary team.4sequencing systemic therapynivolumab leads superior os compared everolimus disease progression one two lines vegf-targeted therapy.1baxitinib, cabozantinib lenvatinib continued immune-related adverse events result cessation axitinib plus pembrolizumab, cabozantinib plus nivolumab lenvatinib plus pembrolizumab. re-challenge immunotherapy requires expert support.4patients receive full four doses ipilimumab due toxicity continue single-agent nivolumab, safe feasible. re-challenge combination therapy requires expert support.4treatment past progression justified requires close scrutiny support expert multidisciplinary team.1bnivolumab plus ipilimumab associated 46% grade iii-iv toxicity 1.5% treatment-related deaths. tyrosine kinase inhibitor-based io combination therapies associated grade iii-v toxicity ranging 61-72% 1% treatment-related deaths.1bin contact 3 study atezolizomab plus cabozantinib offer benefit compared cabozantinib alone patients who’s cancers previously progressed immune checkpoint inhibition therapy.1bcabozantinib single agent robust data first line pd1 based combination therapy.3 recommendationsstrength ratingfirst line treatment metastatic clear cell rcc patientsoffer treatment pd1 combinations centres experience.weakoffer nivolumab plus ipilimumab, pembrolizumab plus axitinib, lenvatinib plus pembrolizumab nivolumab cabozantinib patients international metastatic renal cell carcinoma database consortium (imdc) intermediate- poor risk-disease.strongoffer pembrolizumab plus axitinib, lenvatinib plus pembrolizumab nivolumab cabozantinib sunitinib pazopanib imdc favourable risk disease.weakoffer sunitinib pazopanib patients imdc risk cannot receive tolerate immune checkpoint inhibition.strongoffer cabozantinib patients imdc intermediate- poor-risk clear cell metastatic renal carcinoma (cc-mrcc) cannot receive tolerate immune checkpoint inhibition.strongapatients receive full four doses ipilimumab due toxicity continue single-agent nivolumab, safe feasible. re-challenge combination therapy requires expert support discontinuation toxicity.weaksequencing systemic therapy metastatic clear cell rccsequence systemic therapy treating mrcc.strongoffer carbozantinib vascular endothelial growth factor (vegf)-tyrosine kinase inhibitors second-line therapy patients refractory nivolumab plus ipilimumab axitinib plus pembrolizumab cabozantinib plus nivolumab lenvatinib plus pembrolizumab.weaksequencing agent used second-line therapy (nivolumab cabozantinib) third-line therapy recommended.weakoffer nivolumab cabozantinib patients received first line vegf targeted therapy alone.strongtreatment past progression justified requires close scrutiny support expert multi-disciplinary team.weakdo re-challenge patients stopped immune checkpoint inhibitors toxicity without expert guidance support multi-disciplinary team.strongdo offer pd-l1 combination therapy progression immune checkpoint inhibition combination.weak based randomised phase ii trial, cabozantinib (weak) looks least good sunitinib population. justified recommendation exceptional circumstances. figure 7.1: updated eau guidelines recommendations first-line treatment cc-mrccimdc = international metastatic renal cell carcinoma database consortium.*pazopanib intermediate-risk disease only. [1b] = based one randomised controlled phase iii trial. [2a] = based well-designed study without randomisation, subgroup analysis randomised controlled trial. figure 7.2: eau guidelines recommendations later-line therapyio = immunotherapy; tki = tyrosine kinase inhibitors; vegf = vascular endothelial growth factor. [1b] = based one randomised controlled phase iii trial. [2b] = subgroup analysis randomised controlled phase iii trial. = expert opinion. 7.4.4.1.3. renal tumours sarcomatoid features subset analyses shown improved results pd-l1 inhibitors combined ctla4 vegf-targeted therapy renal tumours sarcomatoid features. ipilimumab/nivolumab, axitinib/pembrolizumab lenvatinib/pembrolizumab avelumab/axitinib recommended instead vefg-targeted therapy alone. options os advantages sunitinib superseded vegf-targeted therapy. nivolumab/ipilimumab provided post hoc analysis demonstrating orr 61%, including 23% cr rate, pfs os benefit sunitinb (hr 0.50 os hr 0.46 respectively median os 48.6 vs 14.2 month . table 7.5:subgroup analysis first-line immune checkpoint inhibitor combinations rcc patients sarcomatoid histology cross trial comparison recommended occur caution studyn(itt)therapyn(srcc)pfs (mo.)median (95% ci)hros (mo.)median (95% ci)hrorr (%)(95% ci)keynote-426nct02853331median follow-up 12.8 months861pembro + axisun5154nr8.4hr: 0.54(0.29-1.00)nrnrhr: 0.58(0.21–1.59)58.831.5javelin 101nct02684006886ave + axisun47617.0 (5.3-13.8)4.0 (2.7-5.7)hr 0.57(0.33-1.00)na46.8 (32.1-61.9)21.3 (11.9-33.7)immotion151nct02420821median follow-up 13 17 months915atezo + bevsun68748.3(5.4, 12.9)5.3(3.3, 6.7)hr: 0.52(0.34-0.79)21.7(15.3, ne)15.4(10.4, 19.5)hr: 0.64(0.41, 1.01)49 (36-1)14 (7-23)checkmate214nct02231749minimum follow-up 60 months1096nivo + ipisunimdc intermediateand poor risk747526.5 (7.2-ne)5.5 (4.1-6.9)hr: 0.50 (0.32‒0.80)48.6 (25.2‒ne)14.2 (9.3‒22.9)hr: 0.46 (0.29‒0.71)60.8 (48.8-72.0)23.1 (13.5-35.2)checkmate 9ernct03141177median follow-up 16 months 651nivo + cabosun344110.3 (5.6-19.4)4.2 (2.6-8.3)hr: 0.42 (0.23-0.74)nr (22.8-ne)19.7 (8.9-29.5)hr: 0.36(0.17-0.79)55.9(37.9-72.8)22.0(10.6-37.6)clearnct02811861median follow-up 27 months712pembro + lensun282111.15.5hr: 0.39(0.18-0.84)nenehr: 0.91(0.32-2.58)60.723.8 atezo = atezolizumab; ave = avelumab; axi = axitinib; bev = bevacizumab; cabo = cabozantinib;ci = confidence interval; hr = hazard ratio; ipi = ipilimumab; itt = intention-to-treat; mo = months;na = available; ne = non-estimable; nr = reached; nivo = nivolumab; os = overall survival;pembro = pembrolizumab; pfs = profession-free survival; srcc = sarcomatoid rcc; sun = sunitinib. 7.4.4.1.3.1. summary evidence recommendation targeted therapy rcc sarcomatoid features summary evidenceleimmune checkpoint inhibitor combination therapy superior sunitinib terms pfs os trial subset analysis clear-cell rcc sarcomatoid features.2a recommendationstrength ratingoffer immune checkpoint inhibitor combination therapy advanced clear cell metastatic renal carcinoma sarcomatoid features.weak